

Supplementary materials

Supplementary Table S1. Antibodies


Epitope	Supplier	Reference	Isotype	kDa	Dilution	Diluent
ATM	Cell signaling	#2873	Rabbit	350	1/1000	BSA 5%
pS1981-ATM	abcam	Ab 81292	Rabbit	370	1/50 000	BSA 5%
ATR	Santa Cruz	Sc-1887	Chèvre	250	1/200	Milk 5%
pS428-ATR	Cell signaling	#2853	Rabbit	300	1/1000	BSA 5%
Chk1	Santa Cruz	Sc-8408	Mouse	56	1/1000	Milk 5%
pS345-Chk1	Cell signaling	#2341	Rabbit	56	1/1000	BSA 5%
Chk2	Millipore	05-649	Mouse	67	1/1000	Milk 5%
pT68-Chk2	Abcam	Ab 3501	Rabbit	61	1/500	Milk 5%
p53	Cell signaling	#2527	Rabbit	53	1/1000	BSA 5%
pS15-p53	Cell signaling	#9284	Rabbit	53	1/1000	Milk 5%
p21 ^{Cip1}	Santa cruz	Sc-756	Rabbit	21	1/500	Milk/BSA 2,5%
pS139-H2AX (γ H2AX)	Santa cruz	Sc-10169	Rabbit	15	1/500	BSA 5%
PARP	Cell signaling	#9542	Rabbit	116,89	1/1000	Milk 5%
GAPDH	Sigma Aldrich	G9545	Rabbit	36	1/1000	Milk 5%
VEGFR2	Cell signaling	#2479	Rabbit	210,230	1/1000	BSA 5%
Hif1 α	Cell signaling	#14179	Rabbit	120	1/1000	BSA 5%
Hif1 β	Abcam	Ab 2771	Mouse	87	1/4000	Milk 5%
STAT3	Cell signaling	#4904	Rabbit	79,86	1/2000	BSA 5%
pY705-STAT3	Cell signaling	#9145	Rabbit	79,86	1/2000	BSA 5%
VEGF-A	Santa cruz	Sc-7269	Mouse	21,42	1/200	Milk 5%
Anti-Mouse IgG HRP	Sigma Aldrich	A0168	Goat		1/10000	Milk 5%
Anti-Rabbit IgG HRP	Cell signaling	#7074	Goat		1/2500	Milk 5%
Anti-Goat IgG HRP	Dako	PO449	Rabbit		1/4000	Milk 5%

Supplementary Table S2. Primers used for RT-qPCR analysis


Gene	Species	Forward sequence	Reverse sequence
<i>VEGFA</i> (VEGF-A)	Human	TTCATGGATGTCTATCAGCG	CATCTCTCCTATGTGCTGGC
<i>GAPDH</i> (GAPDH)	Human	AGATCCCTCCAAAATCAAGTGC	GGCAGAGATGATGACCCTTTT
<i>Vefgr1</i> (VEGFR2)	Mouse	GAGGAGGATGAGGGTGTCTAT	GTGATCAGCTCCAGGTTTGAC
<i>Vefgr2</i> (VEGFR2)	Mouse	GCAAAACACTCACCATTCCCA	GAGGTTTGAAATCGACCCCTCG
<i>Vegfa</i> (VEGF-A)	Mouse	AATGCTTTCTCTGAA	GCTTCTACAGCACAGCACA
<i>Hif1a</i> (HIF1 α)	Mouse	TCTCGGCGAAGCAAAGAGTC	AGCCATCTAGGGCTTTCAGATAA
<i>Epas1</i> (HIF2 α)	Mouse	ACTGGGAGGCATAGCACTGT	TAAAGCGGCAGCTGGAGTAT
<i>Stat3</i> (STAT3)	Mouse	CTGCTCCAGGTAGCGTGTGT	CTCAGCCCCCGGAGACAGT
<i>Nrf2</i> (NRF2)	Mouse	TAGATGACCATGAGTCGCTTGC	GCCAAACTTGCTCCATGTCC
<i>Nrf1</i> (NRF1)	Mouse	AGCACCGAGAGACCCAAAC	TGTACGTGGCTACATGGACCT
<i>Prdx4</i> (PRDX4)	Mouse	CCACCAGCGTAGAAGTGGC	GTTCTGTGTGCGGACCGAAT
<i>Cat</i> (CATALASE)	Mouse	GCTGAAGTTGAACAGATG	GTCATCAGCGTGAGTCTG
<i>Gpx</i> (GPX)	Mouse	CCCTAGGAGAATGGCAAG	CAGAGTGCAGCCAGTAATCACCAAG
<i>Sod1</i> (SOD1)	Mouse	GACCTGGGCAATGTGACTGCTG	CACCAGTGTACGGCCAATGATG
<i>Gapdh</i> (GAPDH)	Mouse	GTTGTCTCCTGCGACTTCA	GGTGGTCCAGGGTTTCTTA

Supplementary Figure S1.


A)




B)



C)



D)



Supplementary Figure S1. Effects of Chrysin on VEGF-A secretion in Human Umbilical Vein Endothelial Cells (HUVEC). HUVEC cells were seeded in 48-well plates (15,000 cells per well) in EBM media (CC-3129 without phenol red, Lonza®) supplemented with EGM SingleQuots (CC-4133, Lonza®) and incubated 24h for cells adhesion. The next day, cells were pretreated without (vehicle control, DMSO 0.05% v/v) or with increasing concentrations of chrysin (0.1, 1, 5, 10, 20, 40 and 80 µM) for 24h. After chrysin pretreatment, cells were either incubated for additional 24h with human recombinant VEGF-165 (rVEGF, 11858821, Invitrogen) at 25 (**A, B**) or 50 ng/mL (**C, D**), or treated with vehicle alone (0.1 % water). At the end of the experiment, cells supernatants were collected and the secreted levels of VEGF were quantified by ELISA (Human VEGF ELISA MAX™ Deluxe set, 446504, Biolegend). **B and D**), Data are expressed as a mean ± SEM in pg/mL from one independent experiment with 3 biological replicates per condition. **A and B**), cells viability was assessed in treated wells by crystal violet staining. Data are expressed as a mean percentage relative to control cells (treated with vehicles alone) ± SEM.